title: Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson's disease.
abstract: Problems associated with long-term treatment of advanced Parkinson's disease (PD) include motor complications and psychotic and autonomic symptoms. We switched patients from bromocriptine (BR) or pergolide (PER) to cabergoline (CB) therapy and investigated CB's usefulness in alleviating such problems. Subjects were 30 patients (mean age 68.2 years; 13 receiving BR, 17 PER) with PD complicated by effects of long-term treatment but in whom their dose of dopamine (DA) agonist was contraindicated due to adverse reactions. Patients were switched to CB over a 2-4-week period. Hoehn-Yahr and Unified Parkinson Disease Rating Scale (UPDRS) I-IV "on" and "off" scores improved in both the BR and PER groups. CB was not discontinued due to adverse reactions in any patient. In conclusion, switching to CB is useful in patients in whom it is problematic to increase their dose of DA agonist due to motor complications or psychotic symptoms of advanced PD.
authors.affiliation: Department of Neurology, St. Marianna University School of Medicine, Miyamae Ward, Kawasaki City, Japan. shira@marianna-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Shiraishi
authors.forename: T
authors.initials: T
authors.lastname: Kamo
authors.forename: M
authors.initials: M
authors.lastname: Hotta
authors.forename: S
authors.initials: S
authors.lastname: Nemoto
authors.forename: J
authors.initials: J
authors.lastname: Oshima
authors.forename: H
authors.initials: H
authors.lastname: Sugihara
authors.forename: S
authors.initials: S
authors.lastname: Yasaki
authors.forename: M
authors.initials: M
authors.lastname: Kawakami
authors.forename: Y
authors.initials: Y
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Shimojo
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology*; D001971:Bromocriptine / Q000009:adverse effects / Q000494:pharmacology; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects* / Q000494:pharmacology*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects / Q000494:pharmacology; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D004873:Ergolines; D010479:Pergolide; D001971:Bromocriptine; D000077465:Cabergoline